期刊文献+

新辅助化疗对口腔鳞癌环氧化酶2的影响及意义

Effects of neoadjuvant chemotherapy on COX-2 expression in oral squamous cell carcinoma and its significance
下载PDF
导出
摘要 目的:探讨新辅助化疗对口腔鳞癌环氧化酶2(cycloxygenase 2,COX-2)、增殖细胞核抗原Ki-67表达和微血管密度(microvessel density,MVD)的影响及临床意义。方法:对从2004年1月-2007年6月间联合应用长春新碱和氨甲蝶呤行新辅助化疗的25例口腔鳞癌患者(辅助化疗组)与既往术前未作任何辅助治疗的28例口腔鳞癌患者(对照组)进行回顾性研究,应用免疫组织化学法检测两组肿瘤标本中的COX-2(光密度)、Ki-67(增殖指数)表达和微血管密度(MVD)。结果:辅助化疗组COX-2、Ki-67表达和MVD分别为(2.63±0.50)×10^5、(34.3±7.1)%和(25.6±4.2)条/HP,显著小于对照组的(3.47±0.67)×10^5、(44.6±9.6)%和(33.8±5.9)条/HP。COX-2与Ki-67和MVD均为正相关关系,相关系数分别为0.574(P〈0.0001)和0.462(P=0.0005)。结论:新辅助化疗可能通过抑制COX-2的表达及降低肿瘤细胞增殖活性,达到减少肿瘤新生血管生成的作用。 Objective: To explore the effects of neoadjuvant chemotherapy ( NAC ) on cycloxygenase 2 ( COX - 2 ) expression, Ki - 67 expression and microvessel density (MVD) in oral squamous cell carcinoma and its significance. Methods:25 patients with squamous carcinoma in oral cavity (NAC group ) were treated with vincristine and methotrexate chemotherapy before operation from January 2004 to June 2007. In control group,28 patients with the same carcinoma did not receive any NAC before operation in the past. Retrospective study was performed in both groups. The OD value of COX - 2, proliferation index of Ki - 67 and MVD were detected by i methods. Results : COX - 2, Ki - 67 expressions and MVD in NAC group were (2.63 ± 0.50 )× 10^5, (34.3 ± 7.1 ) % and (25.6± 4.2 ) micrangiums/HP respectively, which were all significantly lower than those in control group[ (3.47 ± 0.67 ) ×10^5 , (44.6 ±9.6 ) % and ( 33.8 ± 5.9 ) mierangiums/HP, respectively ]. Both COX - 2 and Ki - 67 expression had a positive correlation with MVD and the coefficient correlation was 0. 574 ( P 〈 0. 0001 ) and 0. 462 ( P = 0. 0005), respectively. Conclusion : NAC may reduce the tumor angiogenesis by inhibiting COX - 2 expression and decreasing the proliferation activity of tumor cells.
作者 王强 黄红星
出处 《西南国防医药》 CAS 2009年第7期687-689,共3页 Medical Journal of National Defending Forces in Southwest China
关键词 口腔鳞癌 新辅助化疗 环氧化酶2 KI-67 微血管密度 oral squamous cell carcinoma neoadjuvant chemotherapy cycloxygenase 2 Ki - 67 microvessel density
  • 相关文献

参考文献9

  • 1DOHERTY G A,MURRAY F E.Cyclooxygenase as a target for chemo-prevention in colorectal cancer:lost cause or a concept coming of age[J]?Expert Opin Ther Targets,2009,13(2):209-218.
  • 2HU M,PELUFFO G,CHEN H,et al.Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast[J].Proc Natl Acad Sci USA,2009,106(9):3372-3377.
  • 3WEIDNER N.Tumor angiogenesis:review of current applications in tumor prognostication[J].Semin Diagn Pathol,1993,10(4):302-313.
  • 4RUGGERI E M,CARLINI P,POLLERA C F,et al.Long-term survival in locally advanced oral cavity cancer:an analysis of patients treated with neoadjuvant cisplatin-based chemotherapy followed by surgery[J].Head Neck,2005,27(6):452-458.
  • 5MIAO R,LIU N,WANG Y,et al.Coexpression of cyclooxygenase-2 and vascular endothelial growth factor in gastrointestinal stromal tumor:possible relations to pathological parameters and clinical behavior[J].Hepatogastroenterology,2008,55(88):2012-2015.
  • 6WAGEMAKERS M,VAN DER WAL G E,CUBERES R,et al.COX-2 inhibition combined with radiation reduces orthotopic glioma outgrowth by targeting the tumor vasculature[J].Transl Oncol,2009,2(1):1-7.
  • 7蔡凤林,周士福,马兆生,时伟锋,吴玉玉,高玮红.乳腺癌COX-2和MMP-2的表达与新辅助化疗的关系[J].中国肿瘤临床与康复,2008,15(4):325-327. 被引量:2
  • 8尹子毅,刘晖,李洪利,王丕琳,张铁,宋茂民.乳腺癌组织p53和Ki-67表达及其与新辅助化疗关系的研究[J].中华肿瘤防治杂志,2008,15(9):676-678. 被引量:10
  • 9HALIN S,RUDOLFSSON S H,VAN ROOIJEN N,et al.Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model[J].Neoplasia,2009,11(2):177-186.

二级参考文献16

  • 1李莉,祝峙,方国恩,施俊义,盛援.COX-2和p53在乳腺癌组织中的表达及其相关性[J].中华肿瘤防治杂志,2006,13(4):287-289. 被引量:10
  • 2王新友,王岭,陈江浩,姚青,易军,王辉.CEF方案新辅助化疗对乳腺癌患者血浆基质金属蛋白酶-2,-9活性的影响[J].中国现代医学杂志,2006,16(18):2741-2743. 被引量:3
  • 3王丕琳,李玉文,尹子毅,张铁,朱强,智迎辉.表柔比星联合紫杉醇对浸润性乳腺癌新辅助化疗临床研究[J].中华肿瘤防治杂志,2007,14(9):698-700. 被引量:5
  • 4[3]Anelli A,Brentani R R,Gadelha A P,et al.Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer[J].Ann Oncol,2003,14 (3):428-432.
  • 5[4]Hensel M,Schnee Weiss A,Sinnhp,et al.P53 is the strongest predictorof survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support[J].Int J Cancer,2002,100 (3):290-296.
  • 6[5]Faneyte I F,Schrama J G,Peterse J L,et al.Breast cancer response to neoadjuvant chemotherapy:predictive markers and relation with outcome[J].Br J Cancer,2003,88 (9):406-412.
  • 7[6]Bottini A,Berruti A,Bersiga A,et al.Relationship between tumour shrinkage and reduction in Ki-67 expression after primary chemotherapy in human breast cancer[J].Br J Cancer,2001,85 (8):1106-1112.
  • 8[7]Bhatavdekar J M,Pateld D,Shahng,et al.Prognos-tic significance of immunohisto-chemically localized biomarkers in stage Ⅱ and stage Ⅲ breast cancer:amultivariate analysis[J].Ann Surgoncol,2000,7 (4):305-311.
  • 9Xi H, Baldus SE, Warnecke-Eberz U, et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer[J]. Clin Cancer Res,2005,11(23) :8341-8347.
  • 10Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients[ J]. Clin Cancer Res,2000,6 (10) :4064-4068.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部